Sanofi
TREATMENT OF TYPE 2 DIABETES MELLITUS
Last updated:
Abstract:
The present invention relates to a pharmaceutical combination, comprising (a) a pharmaceutical formulation comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (b) an SGLT2 inhibitor, or/and a pharmaceutically acceptable salt thereof.
Status:
Application
Type:
Utility
Filling date:
9 Sep 2020
Issue date:
1 Apr 2021